Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
BECLOVENT is a metered-dose aerosol inhaled corticosteroid approved in 1980 for respiratory indications. The drug is a small-molecule corticosteroid delivered via inhalation, providing localized anti-inflammatory effects in the lungs. Generic indications likely include asthma and/or COPD, though specific indications are not documented in available data.
Product is nearing loss of exclusivity with moderate competitive pressure (30/100); expect declining commercial headcount and shift toward generic transition planning and lifecycle management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on BECLOVENT in a declining lifecycle offers limited growth opportunities but provides solid experience in mature product management, competitive positioning, and market defense strategies. Positions are more strategic and cost-focused than innovation-driven, suitable for professionals building expertise in portfolio optimization.
Worked on BECLOVENT at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.